Compare Mesoblast Limited (MESO) vs Qurate Retail Inc Series A (QVCAQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Qurate Retail Inc Series A — how do they compare? Mesoblast Limited trades at $16.36 (market cap $2.17B), while Qurate Retail Inc Series A trades at $0.04 (market cap $698.27K). The key difference: Mesoblast Limited is far larger — about 3107.7× Qurate Retail Inc Series A's market cap, and Mesoblast Limited is trading nearer its 52-week high, Qurate Retail Inc Series A nearer its low. Which is the better fit depends on your goals.
| MESO | QVCAQ | |
|---|---|---|
Market Cap | $2.17B | $698.27K |
Sector | Technology | Consumer Cyclical |
52-Week High | $20.96 | $15.03 |
52-Week Low | $12.88 | $0.05 |
Enterprise Value | $2.17B | $4.73B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
QVCAQ trades at $0.05, down 14.68% today, reflecting severe financial distress with negative equity and consecutive annual losses. The stock shows a bearish technical signal, with most moving averages indicating sell pressure. Recent cash flow improvements stem from financing activities, not operations. The company celebrated 40 years of innovation with a TikTok Shop event, but fundamentals remain weak.
Outlook is highly risky due to persistent net losses, declining revenue, and negative shareholder equity. Investment opportunity is minimal without a turnaround in profitability. Key risks include high debt burden, competitive pressures in retail, and inability to achieve sustained earnings growth. Investors should avoid until operational stability is demonstrated.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Qurate Retail Inc Series A
Qurate Retail Inc, through its subsidiaries, is engaged in the video and online commerce industries. Its segments include QxH, which includes QVC U.S. and HSN market and sell a wide variety of consumer products in the United States, primarily using their televised shopping programs and via the Internet through their websites and mobile applications
Read more on QVCAQ →
